Kesler Norman & Wride LLC Has $710,000 Holdings in Zoetis Inc. $ZTS

Kesler Norman & Wride LLC cut its position in shares of Zoetis Inc. (NYSE:ZTS) by 81.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,854 shares of the company’s stock after selling 21,988 shares during the period. Kesler Norman & Wride LLC’s holdings in Zoetis were worth $710,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Nova Wealth Management Inc. acquired a new stake in Zoetis in the first quarter valued at approximately $25,000. Halbert Hargrove Global Advisors LLC raised its holdings in shares of Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after purchasing an additional 144 shares in the last quarter. REAP Financial Group LLC lifted its stake in shares of Zoetis by 201.5% in the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after purchasing an additional 131 shares during the last quarter. NewSquare Capital LLC boosted its holdings in Zoetis by 69.1% in the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock worth $32,000 after purchasing an additional 85 shares in the last quarter. Finally, 1248 Management LLC bought a new stake in Zoetis in the first quarter worth $35,000. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

NYSE ZTS opened at $127.10 on Friday. The stock has a 50-day simple moving average of $123.29 and a 200 day simple moving average of $140.60. Zoetis Inc. has a twelve month low of $115.25 and a twelve month high of $177.40. The stock has a market capitalization of $56.01 billion, a PE ratio of 21.40, a P/E/G ratio of 2.59 and a beta of 0.97. The company has a debt-to-equity ratio of 1.31, a quick ratio of 2.28 and a current ratio of 3.64.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 EPS for the quarter, topping the consensus estimate of $1.62 by $0.08. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The company had revenue of $2.40 billion for the quarter, compared to the consensus estimate of $2.42 billion. During the same period in the previous year, the business posted $1.58 EPS. The company’s revenue for the quarter was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 3rd. Investors of record on Tuesday, January 20th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 1.7%. The ex-dividend date is Tuesday, January 20th. This is an increase from Zoetis’s previous quarterly dividend of $0.50. Zoetis’s dividend payout ratio is currently 33.67%.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on ZTS shares. UBS Group cut their target price on Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a report on Wednesday, November 5th. BTIG Research reissued a “buy” rating and set a $160.00 price objective on shares of Zoetis in a report on Wednesday, December 3rd. Weiss Ratings reissued a “sell (d+)” rating on shares of Zoetis in a research note on Monday, December 29th. Barclays assumed coverage on Zoetis in a research report on Monday, December 8th. They set an “equal weight” rating and a $136.00 target price for the company. Finally, KeyCorp started coverage on Zoetis in a report on Thursday, November 20th. They set a “sector weight” rating on the stock. Six analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $160.18.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.